keyword
MENU ▼
Read by QxMD icon Read
search

ARB AND NO

keyword
https://www.readbyqxmd.com/read/29327797/potassium-and-the-use-of-renin-angiotensin-aldosterone-system-inhibitors-in-heart-failure-with-reduced-ejection-fraction-data-from-biostat-chf
#1
Joost C Beusekamp, Jasper Tromp, Haye H van der Wal, Stefan D Anker, John G Cleland, Kenneth Dickstein, Gerasimos Filippatos, Pim van der Harst, Hans L Hillege, Chim C Lang, Marco Metra, Leong L Ng, Piotr Ponikowski, Nilesh J Samani, Dirk J van Veldhuisen, Aeilko H Zwinderman, Patrick Rossignol, Faiez Zannad, Adriaan A Voors, Peter van der Meer
BACKGROUND: Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Whether it affects the use of renin-angiotensin-aldosterone system inhibitors and thereby negatively impacts outcome is unknown. Therefore, we investigated the association between potassium and uptitration of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) and its association with outcome. METHODS AND RESULTS: Out of 2516 patients from the BIOSTAT-CHF study, potassium levels were available in 1666 patients with HFrEF...
January 12, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29310811/effect-of-renin-angiotensin-system-inhibitors-on-survival-in-kidney-transplant-recipients-a-systematic-review-and-meta-analysis
#2
REVIEW
Ya-Mei Jiang, Tu-Run Song, Yang Qiu, Jin-Peng Liu, Xian-Ding Wang, Zhong-Li Huang, Tao Lin
Renin-angiotensin system inhibitors, specifically angiotensin II converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), have confirmed renoprotective benefits in patients with proteinuria and hypertension. However, it remains controversial whether these agents are beneficial to kidney recipients. We conducted this meta-analysis to evaluate the effects of ACEI/ARB treatment on patient and allograft survival after kidney transplant. The PubMed, Embase and Cochrane Library databases were searched for eligible articles from before May 2016, and we included 24 articles (9 randomised controlled trials [RCTs] and 15 cohort studies with 54,096 patients), in which patient or graft survival was compared between an ACEI/ARB treatment arm and a control arm...
January 2018: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/29282632/effects-of-cilostazol-and-renin-angiotensin-system-ras-blockers-on-the-renal-disease-progression-of-korean-patients-a-retrospective-cohort-study
#3
Yoojin Noh, Jimin Lee, Sooyoung Shin, Inwhee Park, Soo Kyung Bae, Euichul Oh, Sukhyang Lee
Background Decline in estimated glomerular filtration rate (eGFR) is an important surrogate marker for the assessment of renal function. Addition of a second agent to angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) treatment may improve current therapeutic strategies aimed at suppressing renal disease progression. Objective To determine the effect of cilostazol in combination with ACEI or ARB treatment on the decline in eGFR. Setting A tertiary hospital in Korea. Method In an observational cohort study, we analyzed 5505 patients who were prescribed ACEI or ARB and cilostazol or other antiplatelet agents...
December 27, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29246770/a-longitudinal-cohort-study-of-aspirin-use-and-progression-of-emphysema-like-lung-on-ct-the-mesa-lung-study
#4
Carrie P Aaron, Joseph E Schwartz, Eric A Hoffman, Elsa Angelini, John H M Austin, Mary Cushman, David R Jacobs, Joel D Kaufman, Andrew Laine, Lewis J Smith, Jie Yang, Karol E Watson, Russell P Tracy, R Graham Barr
BACKGROUND: Platelet activation reduces pulmonary microvascular blood flow and contributes to inflammation, which have been implicated in the pathogenesis of chronic obstructive pulmonary disease and emphysema. We hypothesized that regular use of aspirin, a platelet-inhibitor, would be associated with slower progression of emphysema-like lung on computed tomography (CT) and slower decline in lung function. METHODS: The Multi-Ethnic Study of Atherosclerosis (MESA) enrolled participants 45-84 years old without clinical cardiovascular disease in 2000-02...
December 12, 2017: Chest
https://www.readbyqxmd.com/read/29240784/effects-of-calcium-channel-blockers-comparing-to-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-in-patients-with-hypertension-and-chronic-kidney-disease-stage-3-to-5-and-dialysis-a-systematic-review-and-meta-analysis
#5
Yen-Chung Lin, Jheng-Wei Lin, Mai-Szu Wu, Kuan-Chou Chen, Chiung-Chi Peng, Yi-No Kang
BACKGROUND: Calcium channel blocker (CCB) or two renin angiotensin aldosterone system blockades (RAAS), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are major potent and prevalently used as initial antihypertensive agents for mild to moderate hypertension, but no uniform agreement as to which antihypertensive drugs should be given for initial therapy, especially among chronic kidney disease (CKD) patients. DESIGN: A systematic review and meta-analysis comparing CCBs and the two RAAS blockades for hypertensive patients with CKD stage 3 to 5D...
2017: PloS One
https://www.readbyqxmd.com/read/29222139/effect-of-losartan-on-rv-dysfunction-results-from-the-double-blind-randomized-redefine-trial-in-adults-with-repaired-tetralogy-of-fallot
#6
Jouke P Bokma, Michiel M Winter, Arie P van Dijk, Hubert W Vliegen, Joost P van Melle, Folkert Meijboom, Martijn C Post, Jacqueline K Berbee, S Matthijs Boekholdt, Maarten Groenink, Aeilko H Zwinderman, Barbara J M Mulder, Berto J Bouma
Background -The effect of angiotensin II receptor blockers (ARBs) on right ventricular (RV) function is still unknown. ARBs are beneficial in patients with acquired left ventricular (LV) dysfunction and recent findings suggested a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an ARB, on subpulmonary RV dysfunction in adults after repair of tetralogy of Fallot (rTOF). Methods -REDEFINE is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study...
December 8, 2017: Circulation
https://www.readbyqxmd.com/read/29218625/diuretic-or-beta-blocker-for-hypertensive-patients-already-receiving-acei-arb-and-calcium-channel-blocker
#7
Min-Shan Tsai, Chao-Hsiun Tang, Chia-Ying Lin, Po-Ya Chuang, Nai-Chuan Chen, Chien-Hua Huang, Wei-Tien Chang, Tzung-Dau Wang, Ping-Hsun Yu, Wen-Jone Chen
BACKGROUND: In patients already receiving combination of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) and calcium channel blocker (CCB), whether the choice of additional diuretic or beta-blocker affects the cardiovascular and cerebrovascular outcomes remains unclear. METHODS: A total of 13,551 patients who were concurrently receiving three anti-hypertensive agents of different classes through outpatient clinics during 2004-2006 were identified from the National Health Insurance Research Database of Taiwan...
December 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29204682/pharmacist-led-intervention-in-the-multidisciplinary-team-approach-optimizes-heart-failure-medication
#8
Masanori Suzuki, Yuya Matsue, Sayaka Izumi, Ayako Kimura, Tomoaki Hashimoto, Kentaro Otomo, Hiroshi Saito, Makoto Suzuki, Yasuhisa Kato, Ryohkan Funakoshi
We evaluated the impact of pharmacist-led heart failure (HF) drug recommendations during hospitalization for hospitalized patients with HF. Hospitalized patients with HF were retrospectively reviewed. Patients were hospitalized before (n = 208, non-intervention group) or after (n = 170, intervention group) the launch of the HF multidisciplinary team (HFMDT) approach with pharmacist-led HF medication optimization. There were no significant group differences in patient background characteristics at admission...
December 4, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/29179525/aliskiren-therapy-in-hypertension-and-cardiovascular-disease-a-systematic-review-and-a-meta-analysis
#9
REVIEW
Shufang Fu, Xin Wen, Fei Han, Yin Long, Gaosi Xu
The efficacy and safety of aliskiren combination therapy with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with hypertension and cardiovascular disease remains attractive attention. We searched the Cochrane Central Register, the Clinical Trials Registry, EMBASE, MEDLINE and PubMed for relevant literatures up to January 2017. A total of 13 randomized controlled trials (RCTs) with 12222 patients were included in this study, and the combined results indicated that aliskiren in combination therapy with ACEIs or ARBs had remarkable effects in reducing systolic blood pressure (SBP) [weighted mean differences (WMD), -4...
October 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/29175038/renin-angiotensin-system-blockade-does-not-attenuate-abdominal-aortic-aneurysm-growth-rupture-rate-or-perioperative-mortality-after-elective-repair
#10
REVIEW
Konrad Salata, Muzammil Syed, Mohamad A Hussain, Rachel Eikelboom, Charles de Mestral, Subodh Verma, Mohammed Al-Omran
OBJECTIVE: The objective of this study was to summarize the literature regarding the effects of renin-angiotensin system blockade (RASB) using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) on human abdominal aortic aneurysm (AAA) growth, rupture, and perioperative mortality. METHODS: We conducted a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Our review protocol was registered at the International Prospective Register of Systematic Reviews (CRD42016054082)...
November 23, 2017: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/29172402/olmesartan-is-not-associated-with-the-risk-of-enteropathy-a-korean-nationwide-observational-cohort-study
#11
Seng Chan You, Hojun Park, Dukyong Yoon, Sooyoung Park, Boyoung Joung, Rae Woong Park
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea. Methods: Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012...
November 27, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29163738/a-case-of-moderate-sprue-like-enteropathy-associated-with-telmisartan
#12
Aurelio Negro, Loredana De Marco, Valentina Cesario, Rosaria Santi, Maria Chiara Boni, Magda Zanelli
Sprue-like enteropathy associated with olmesartan medoxomil use has been recently reported. Its clinical manifestations include diarrhea, weight loss and malabsorption. Duodenal biopsies show villous atrophy (VA) with or without intraepithelial lymphocytosis and inflammation of the lamina propria. Serology for celiac disease (CD) is negative and gluten-free diet does not result in clinical improvement. Symptoms resolve after olmesartan discontinuation. Follow-up biopsies show recovery/improvement of the duodenum...
December 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29158710/the-impact-of-pharmacists-providing-direct-patient-care-as-members-of-interprofessional-teams-on-diabetes-management
#13
Osamah M Alfayez, Majed S Al Yami, Maryam T Fazel
The purpose of this study was to evaluate the impact of pharmacist providing direct patient care as a member of interprofessional team on diabetes management. This study is a retrospective chart review of diabetes patients seen by a pharmacist in an endocrinology clinic affiliated with an academic medical center. The following patient outcomes were recorded pre and post the pharmacist intervention: glycemic control as measured by change in hemoglobin A1c (HbA1c), change in systolic blood pressure (SBP) and diastolic blood pressure (DBP), statin use, and use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)...
November 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/29155121/evaluation-of-protein-c-and-protein-s-levels-in-patients-with-diabetes-mellitus-receiving-therapy-with-statins-and-ace-inhibitors-or-angiotensin-ii-receptor-blockers
#14
Şerife Aktaş, Sema Uçak, Fatma Kurt, Mehmet Taşdemir, Orkide Kutlu, Pınar Eker
AIMS: To evaluate protein C, protein S level in patients with diabetes mellitus receiving statin and ACE inhibitor/ARB therapy. METHODS: 95 patients were included in the study and divided into four groups depending on the use of statin and ACE inhibitor/ARB therapy. Group 1 comprised of patients receiving statin therapy (n = 15), Group 2 comprised of patients receiving ACE inhibitor/ARB therapy (n = 31), Group 3 comprised of patients receiving statin and ACE inhibitor/ARB therapy (n = 23), and Group 4 comprised of patients who did not receive either statin or ACE inhibitor/ARB therapy (n = 26)...
November 15, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29153114/cost-effectiveness-analyses-of-antihypertensive-medicines-a-systematic-review
#15
REVIEW
Chanhyun Park, Guijing Wang, Jefferey M Durthaler, Jing Fang
CONTEXT: Hypertension affects one third of the U.S. adult population. Although cost-effectiveness analyses of antihypertensive medicines have been published, a comprehensive systematic review across medicine classes is not available. EVIDENCE ACQUISITION: PubMed, Embase, Cochrane Library, and Health Technology Assessment were searched to identify original cost-effectiveness analyses published from 1990 through August 2016. Results were summarized by medicine class: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), thiazide-type diuretics, β-blockers, and others...
December 2017: American Journal of Preventive Medicine
https://www.readbyqxmd.com/read/29142983/efficacy-and-safety-of-sparsentan-compared-with-irbesartan-in-patients-with-primary-focal-segmental-glomerulosclerosis-randomized-controlled-trial-design-duet
#16
Radko Komers, Debbie S Gipson, Peter Nelson, Sharon Adler, Tarak Srivastava, Vimal K Derebail, Kevin E Meyers, Pablo Pergola, Meghan E MacNally, Jennifer L Hunt, Alvin Shih, Howard Trachtman
Introduction: Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administration-approved therapies for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in the pathophysiology of podocyte disorders, including FSGS. Sparsentan is a first-in-class, orally active, dual-acting angiotensin receptor blocker (ARB) and highly selective endothelin Type A receptor antagonist...
July 2017: KI Reports
https://www.readbyqxmd.com/read/29137346/safety-of-the-neprilysin-renin-angiotensin-system-inhibitor-lcz696
#17
REVIEW
Bo Li, Yunhe Zhao, Bo Yin, Mengfei Helian, Xinmei Wang, Feng Chen, Hongxia Zhang, Hui Sun, Bin Meng, Fengshuang An
Objectives: The combined neprilysin/rennin-angiotensin system inhibitor sacubitril/valsartan (LCZ696) has shown its superiority over ACEI/ARB therapy. In view of the existing concern of its adverse effects, we aimed to provide evidence of the safety of the new drug. Results: A total of 6 randomized trials with 11,821 subjects were included in this analysis. No significant differences were found in any adverse effects between LCZ696 and ACEI/ARB or placebo groups...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29121522/effects-of-vitamin-k-antagonist-on-aortic-valve-degeneration-in-non-valvular-atrial-fibrillation-patients-prospective-4-year-observational-study
#18
Kazuhiro Yamamoto, Yukihiro Koretsune, Takashi Akasaka, Akira Kisanuki, Nobuyuki Ohte, Takashi Takenaka, Masaaki Takeuchi, Kiyoshi Yoshida, Kazunori Iwade, Yuji Okuyama, Yutaka Hirano, Yasuharu Takeda, Yasumasa Tsukamoto, Yoshiharu Kinugasa, Satoshi Nakatani, Takashi Sakamoto, Katsuomi Iwakura, Takashi Sozu, Tohru Masuyama
BACKGROUND: The prevalence of atrial fibrillation (AF) is high in elder subjects. Our previous observational study suggested that vitamin K antagonist (VKA) promotes aortic valve degeneration, a principal cause of aortic stenosis in the elderly, and that angiotensin receptor blocker (ARB) attenuates its progression. This study aimed to prospectively investigate these observations in non-valvular AF patients. METHODS: Of enrolled 430 patients with calcification on no or one aortic valve leaflet, all of the planned 4-year follow-up data were obtained in 122 non-valvular AF patients treated with warfarin (warfarin group) and 101 patients with cardiovascular diseases and without AF and prescription of warfarin (non-warfarin group)...
November 6, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/29118227/nonadherence-to-statins-and-antihypertensives-and-hospitalizations-among-elderly-medicare-beneficiaries-with-incident-cancer
#19
Ishveen Chopra, Nilanjana Dwibedi, Malcolm D Mattes, Xi Tan, Patricia Findley, Usha Sambamoorthi
Background: Incident cancer diagnosis may increase the risk of coronary artery disease (CAD)-related hospitalizations, especially in older individuals. Adherence to statins and/or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/β-blockers reduces CAD-related hospitalizations. This study examined the relationship between medication adherence and CAD-related hospitalizations immediately following cancer diagnosis. Patients and Methods: A retrospective observational longitudinal study was conducted using SEER-Medicare data...
November 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29046519/the-effects-of-anti-hypertensive-drugs-and-the-mechanism-of-hypertension-in-vascular-smooth-muscle-cell-specific-atp2b1-knockout-mice
#20
Yuki Okuyama, Nobuhito Hirawa, Megumi Fujita, Akira Fujiwara, Yosuke Ehara, Keisuke Yatsu, Koichiro Sumida, Minako Kagimoto, Mari Katsumata, Yusuke Kobayashi, Sanae Saka, Satoshi Umemura, Kouichi Tamura
ATP2B1 is a gene associated with hypertension. We reported previously that mice lacking ATP2B1 in vascular smooth muscle cells (VSMC ATP2B1 KO mice) exhibited high blood pressure and increased intracellular calcium concentration. The present study was designed to investigate whether lack of the ATP2B1 gene causes a higher response to calcium channel blockers (CCBs) than to other types of anti-hypertensive drugs. Both VSMC ATP2B1 KO and control mice were administered anti-hypertensive drugs while monitoring blood pressure shifts...
October 19, 2017: Hypertension Research: Official Journal of the Japanese Society of Hypertension
keyword
keyword
91287
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"